VisionCare Ophthalmic Technologies, Inc., a developer of ophthalmic telescope implant, has received a Health Canada medical device license to market the implantable miniature telescope in Canada.
According to the company, the telescope implant is an integral component of a new patient care program called CentraSight, which has been developed to improve vision and quality of life in patients with end-stage age-related macular degeneration (AMD).
The CentraSight treatment program involves a patient management process and access to reimbursement information for patients and physicians, the company said.
Smaller than a pea, the telescope implant uses micro-optical technology to magnify images which would normally be seen in one's straight ahead or central, vision. The images are projected onto the healthy portion of the retina not affected by the disease, making it possible for patients to see or discern the central vision object of interest, the company said.
"The grant of the license from Health Canada to market our implantable telescope in the Canadian market is an important step forward," said Allen Hill, VisionCare's CEO. "Our company is moving forward both with the ophthalmic community and reimbursement authorities as we prepare for market introduction. We are excited to have the opportunity to provide this technology and related CentraSight treatment program to patients in Canada living with this devastating disease."